A collaboration between the Max Planck Institute for Biology of Ageing and University College London demonstrates that trametinib inhibits RAS/Mek/Erk and rapamycin blocks mTORC1, and together these drugs additively extend healthspan and lifespan in C3B6F1 mice by reducing tumors, inflammation, and age-related metabolic decline.

Key points

• Oral trametinib at 1.44 mg/kg diet extends median lifespan by ~10% in male and ~7% in female C3B6F1 mice.
• Intermittent rapamycin dosing (42 mg/kg weekly) combined with trametinib yields additive median lifespan gains of 27–35%.
• Combination therapy reduces liver and spleen tumor incidence, blocks age-related brain glucose uptake increases, and lowers systemic pro-inflammatory cytokines.

Why it matters: Dual targeting of RAS/Mek/Erk and mTORC1 pathways offers a promising additive gerotherapeutic strategy with translational potential to enhance mammalian healthspan beyond single-drug approaches.

Gov.Capital’s analysis spotlights four pioneering biotech firms leveraging CRISPR-Cas9 and base-editing platforms to develop therapies aimed at molecular drivers of aging, such as PCSK9 and transthyretin. It examines in vivo lipid nanoparticle delivery, ex vivo edited stem cells, and key clinical programs for cardiovascular disease, amyloidosis, and immuno-oncology to guide investment decisions.

Key points

• In vivo base editing of PCSK9 and ANGPTL3 via lipid nanoparticles achieves durable lipid reduction in early trials.
• Ex vivo CRISPR-Cas9 editing of hematopoietic stem cells induces fetal hemoglobin to treat sickle cell and beta-thalassemia.
• Phase 3 in vivo Cas9 therapy for transthyretin amyloidosis demonstrates clinical proof-of-concept with significant TTR protein knockdown.

Why it matters: CRISPR-based gene therapies promise to transform treatment paradigms by offering single-dose cures for cardiovascular and degenerative age-related diseases, boosting healthspan.

Researchers from Mass General Brigham and the Medical College of Georgia demonstrate that a daily 2,000 IU dose of vitamin D3 significantly preserves telomere length in adults aged 50 and above by mitigating oxidative stress and inflammatory pathways, suggesting a cost-effective approach to promote healthy aging.

Key points

• Mass General Brigham and Medical College of Georgia researchers conducted a five-year VITAL randomized trial analysis.
• Daily oral supplementation of 2,000 IU vitamin D3 preserves telomere length by reducing oxidative stress and inflammation.
• Study participants aged 50+ show up to three years’ worth of delayed telomere shortening, measured via leukocyte telomere assays.

Why it matters: Preserving telomeres could shift anti-aging strategies toward affordable, low-risk interventions with broad chronic disease prevention potential.

A cross-sectional study led by Zagazig University and collaborators conducted a structured online survey of 423 medical students from ten Egyptian universities, assessing their understanding, attitudes, and practices regarding generative artificial intelligence. Findings indicate 61.5% satisfactory knowledge levels, higher scores among males and clinical-phase students, and widespread use of Chat-GPT tools for academic tasks.

Key points

• An 8-question knowledge score, 13-item attitude Likert scale, and 7-item practice frequency scale evaluated generative AI competencies among 423 Egyptian medical students.
• Binary logistic regression revealed male gender (OR=1.87), 6th October University affiliation (OR=3.55), and clinical-phase status (OR=0.54) as significant predictors of satisfactory AI knowledge (p<0.05).
• Students primarily employed Chat-GPT 3.5 (37.1%) and 4 (35.2%) for grammar correction, assignment preparation, research, and idea generation, correlating with knowledge scores (r=0.303, p<0.001).

Why it matters: Understanding medical students’ readiness for generative AI informs curriculum design for future healthcare education and practice.

DelveInsight’s market analysis demonstrates robust growth in AI-driven precision medicine, highlighting how advanced algorithms process genomic and clinical data to optimize personalized diagnostics and therapies, driven by partnerships and FDA clearances in North America leading the global market through 2032.

Key points

• Hardware and software accounted for the largest revenue share in the AI in precision medicine market in 2024.
• North America is projected to dominate the global AI precision medicine market through 2032, driven by R&D and regulatory clearances.
• Major partnerships and FDA 510(k) approvals, including Illumina-Tempus and Ibex Prostate Detect, are accelerating clinical adoption.

Why it matters: The projected 33% CAGR underscores AI's transformative impact on personalized healthcare, promising faster diagnostics and tailored treatments beyond conventional methods.

Researchers at Communication University of Zhejiang apply generative AI in animation teaching by creating adaptive learning pathways, intelligent resource generation, and immersive interactive tools. A mixed-methods trial with 120 students demonstrates significant improvements in knowledge retention, creativity, engagement, and teamwork.

Key points

• Mixed-methods study with 120 students over 12 weeks compares traditional and GAI-enhanced animation teaching.
• Reinforcement learning-based adaptive paths dynamically adjust content difficulty and pacing according to real-time performance data.
• AR-enabled mixed-reality platform synchronizes virtual storyboard collaboration with AI-assisted feedback to strengthen teamwork and creativity.

Why it matters: This study illustrates how AI-driven personalized education can revolutionize creative skill development, engagement, and collaboration in animation training.

Exactitude Consultancy forecasts the global automotive AI hardware market expanding from approximately USD 15 billion in 2024 to USD 40 billion by 2034, based on segmented CAGR analysis of in-vehicle AI chips, sensor hardware, and ECUs, fuelled by ADAS and autonomy integration.

Key points

• Sensor hardware leads with a 40 % share, driving autonomous function enablement.
• ADAS applications represent 50 % of the market, propelled by safety regulations.
• Combined in-vehicle AI chips and ECUs account for over 55 % share, supporting real-time processing.